World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
64167
World Ranking
7173
National Ranking
98

Solange Peters publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Solange Peters sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 461 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Solange Peters D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Solange Peters sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Solange Peters is affiliated with the University Hospital of Lausanne in Switzerland. Their research spans medicine with a strong focus on oncology, pulmonary and respiratory medicine, and cancer research.

The main fields of study include:

  • Medicine

Subfields of study specifically highlight:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

The principal research topics covered by Solange Peters are:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • COVID-19 and healthcare impacts
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Frequent publication venues for their work include:

  • Annals of Oncology
  • ESMO Open
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Revue Médicale Suisse

Frequent coauthors collaborating with Solange Peters comprise:

  • Tony Mok
  • Rolf A. Stahel
  • Urania Dafni
  • Hasna Bouchaab
  • Enriqueta Felip

Among the recent papers involving Solange Peters are:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, 2020, The Lancet
  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet
  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study, 2020, Journal of Clinical Oncology
  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, 2022, The Lancet Oncology

Best Publications

  • Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

    Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  • Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

    T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. B. A. G. Haanen;F. Carbonnel;C. Robert;K. M. Kerr

  • Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

    Filipe Martins;Filipe Martins;Latifyan Sofiya;Gerasimos P. Sykiotis;Faiza Lamine

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim

  • Quantifying the biodiversity value of tropical primary, secondary, and plantation forests.

    J. Barlow;T. A. Gardner;I. S. Araujo;T. C. Ávila-Pires

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

    Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

  • Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Reck;S Popat;N Reinmuth;Dirk De Ruysscher

  • Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

    Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  • Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Früh;Dirk De Ruysscher;S Popat;L Crinò

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

    Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

    Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

    T. Mok;D.R. Camidge;S.M. Gadgeel;R. Rosell

  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

    Naiyer A Rizvi;Byoung Chul Cho;Niels Reinmuth;Ki Hyeong Lee

  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

    E. Le Rhun;M. Weller;D. Brandsma;M. Van den Bent

Frequent Co-Authors

Rolf A. Stahel
Rolf A. Stahel University of Zurich
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Tony Mok
Tony Mok Chinese University of Hong Kong
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Lukas Bubendorf
Lukas Bubendorf University Hospital of Basel
Keith M. Kerr
Keith M. Kerr Aberdeen Royal Infirmary
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Dirk De Ruysscher
Dirk De Ruysscher Maastricht University
Walter Weder
Walter Weder University of Zurich
Olivier Michielin
Olivier Michielin University of Lausanne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees in healthcare is an excellent way to advance your career without relocating or disrupting your current lifestyle. Many students in the United States are now considering these flexible options, especially given the demand for highly qualified nursing professionals.

If you’re interested in advanced practice roles, you might want to research the cheapest online fnp program options. These programs can help you become a Family Nurse Practitioner while keeping tuition costs manageable.

For those just starting in the field, there are many affordable online nursing programs that offer entry-level training and credentials.

Current RNs seeking to upgrade their qualifications should explore rn to bsn online cost to find budget-friendly pathways to your Bachelor of Science in Nursing.

If you’re pursuing a career in academia or leadership, investigate the online phd programs in nursing. These advanced degrees can unlock opportunities in research, teaching, or executive management across healthcare settings.

Best Scientists Citing Solange Peters

Trending Scientists

Recently Published Articles